As I recently discussed elsewhere [1], the likely solutions for the current paucity of new antibacterials may lie in the hands of a global initiative, whether this be led by the World Health Organization or the International Committee on Harmonization. It is clear that regulatory hurdles still present a major deterrent to the pharmaceutical industry; however, there is another issue that is often overlooked.As I recently discussed elsewhere [1], the likely solutions for the current paucity of new antibacterials may lie in the hands of a global initiative, whether this be led by the World Health Organization or the International Committee on Harmonization. It is clear that regulatory hurdles still present a major deterrent to the pharmaceutical industry; however, there is another issue that is often overlooked.
展开▼
